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Rating
￿Of importance.
Introduction
Hypertension, defined as systolic blood pressure (SBP)
greater than 140 mm Hg or diastolic blood pressure (DBP)
greater than 90 mm Hg, remains a significant problem that
results in increased risk of cardiovascular disease [1].
Despite heightened recognition of this problem, less than
40% of patients are at their goal blood pressure (BP) [2].
There are multiple pharmacologic treatments for hyperten-
sion, and it has been known for some time that a patient’s
likelihood to respond to a particular treatment may depend
on that patient’s ethnic background [3]. This information
has been used to guide initial monotherapy in different
racial groups in order to provide optimal treatment, but
there is little information regarding combination therapies
across different ethnicities. Many patients require multiple
drugs to achieve BP less than 140/90, and some guidelines
suggest beginning treatment with a combination of two drugs
if the initial BP is more than 20/10 points above goal [4].
The ASCOT (Anglo-Scandinavian Cardiac Outcomes
Trial) study evaluated BP reduction in response to mono-
therapy as well as specific combinations of BP drugs in
three different ethnic groups (European origin, African
origin, and those from the Indian subcontinent) to evaluate
whether a patient’s ethnicity plays a role in the outcomes of
initial or combination BP therapy.
Aims
To determine whether BP response in patients during initial
monotherapy or during combination treatment with a
second-line drug differs by ethnic group (white, black, or
South Asian).
Methods
The study examines data from centers in the United
Kingdom involved in the BP-lowering arm of ASCOT, in
which 5,425 patients of European (white), African (black),
or Indian subcontinent (South-Asian) ancestry were initially
randomized to receive monotherapy with either the beta-
adrenergic antagonist atenolol or the calcium channel
blocker (CCB) amlodipine. Of this group, 742 patients
changed monotherapy drugs and were not included in the
analysis, leaving 4,683 patients for analysis, and 4,168
patients went on to receive dual therapy per study protocol.
Only 2,794 patients were included in dual-therapy analysis
because of lack of blood pressure logs and changes in
medications. Patients who did not achieve targeted BP
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converting enzyme (ACE) inhibitor perindopril was added
to the amlodipine group, or the thiazide diuretic bendro-
flumethiazide was added to the atenolol group. BP was
measured at every study visit. The result of monotherapy or
BP treated by second-line therapy was measured using the
BP on the day of uptitration of treatment to the next level.
The final change in BP was measured by subtracting the BP
at the beginning of the study from the BP at the end of
therapy. Ethnicity was self-determined by a patient ques-
tionnaire. Patients were placed into ethnic groups. The
study defined whites as individuals of European origin,
blacks as individuals of African origin, and South Asians as
individuals from the Indian Subcontinent.
The study examined patient response to monotherapy
and second-line therapy in all three ethnic groups. Therapy
was adjusted in a step-wise fashion per study protocol. Data
from patients who switched from one medication arm to
another were examined using an intention-to-treat analysis.
The study authors used two linear regression models: BP
was the dependent variable; ethnicity and allocated treat-
ments were independent variables. The first model con-
trolled for age, gender, body mass index, and years of
education. The second model adjusted for these variables as
well as duration of dual therapy, previous hypertension
treatment, presence of diabetes, and diastolic BP at the start
of therapy.
Results
Of the original 5,425 participants, 5,021 were white, 250
were black, and 154 were South-Asian. Of these, 2,580
were randomized to atenolol and 2,845 to amlodipine;
4,683 (86.3%) of these participants remained on the
original drug and were included in analysis. Additional
treatment was required by 4,168 patients and was added as
described above. In this group, 2,794 continued on the
combination regimen and had adequate blood pressure logs.
During monotherapy, all three groups had similar
responses to amlodipine. Blacks did not respond as well
to atenolol as whites and South-Asians (P=0.02): the SBP
for blacks increased by 4.5 mm Hg and there was no
change in DBP, compared with decreases of SBP/DBP of
1.6/3.6 mm Hg in whites and 4.5/3.6 mm Hg in South-
Asians. The difference was statistically significant when
confounding variables were corrected for in both linear
regression models. DBP did not differ between the three
groups on atenolol monotherapy (P=0.02).
In response to adding a second-line drug, there were no
significant differences across the three ethnic groups when
adding bendroflumethiazide to atenolol, prior to adjusting
for confounders. When adjusting for confounders in model 1,
blacks had the greatest benefit and South-Asians the
least, but statistical significance was lost upon further
correction with model 2. In patients who had perindopril
added to amlodipine, there were differences (P=0.002) in
reduction of SBP and DBP based on ethnic group: whites
had a reduction of 10.2/5.6 mm Hg, blacks 3.2/
2.5 mm Hg, and South-Asians 11.2/4.8 mm Hg. The
change in SBP was statistically significant across groups
(P=0.004), but the change in DBP was not.
Discussion
This study evaluated differences in response to first-line
and second-line hypertension treatment in large numbers of
patients stratified by ethnicity. The first difference noted
was during monotherapy. Black patients responded less
well to atenolol than whites and South-Asians, a finding
that is consistent with prior reports [3]. Decreased response
of black hypertensives to ACE inhibitors has previously
been shown in studies examining initial monotherapy [3],
but it had not yet been shown after adding an ACE inhibitor
as a second-line drug. These findings strengthen the idea of
using different antihypertensive drugs in different ethnic
groups to provide the most benefit, an idea that has already
been documented with initial monotherapy [3] but not with
combinations of medicines.
Two editorials accompanying the paper argue that the
difference between ethnic groups in their response to
antihypertensive treatment may be due in part to differences
between the groups in renin levels [5, 6]. Both note that
blacks, as defined in ASCOT, tend to have low-renin
hypertension compared with whites, and this could be the
reason for the difference in response to treatment.
Though some physicians may already be using drugs
that have been more effective in monotherapy as a
combination, rather than the classic “AB/CD” combination
tool of pairing either an ACE inhibitor or a beta blocker
with a CCB or a diuretic [6, 7], ASCOT is one of the few
studies to show that the sequential addition of medications
based on ethnicity may be a useful strategy.
Comment
This paper continues to build on the established idea that
antihypertensive therapy should be adjusted based on
patient ethnicity. ASCOT expands this concept beyond
initial monotherapy to combination therapies. The results
also open the door for further study in tailoring multidrug
hypertensive therapy.
The study authors suggest that the use of a CCB plus a
diuretic may be a more effective combination in black
Curr Hypertens Rep (2011) 13:8–10 9patients than a beta blocker plus an ACE inhibitor. This
limited conclusion leads to one weakness of the paper,
however, which is that only two combinations (diuretic and
CCBvsbetablockerandACEinhibitor)werestudied.Further
study is needed before clinical guidelines can be adopted
regardingtheadditionofsecond-lineantihypertensivetherapy
based on ethnicity. The need for further study is even more
apparent now, as recent studies in hypertension that formally
examinedguidelinesobtainedfromepidemiologicstudiesand
expert opinion in areas such as chronic kidney disease have
had surprising results [8]. Also, ASCOT contrasts with the
recent ACCOMPLISH trial, which suggests that an ACE
inhibitor and a CCB is a more ideal combination, at least in
patients at higher risk for cardiovascular events [9]. The
ASCOT and ACCOMPLISH trials are not directly compa-
rable, however, as ACCOMPLISH studied ACE inhibitor/
diuretic and ACE inhibitor/CCB combinations, whereas
ASCOT compared an ACE inhibitor/CCB combination
versus a beta blocker/diuretic combination. Finally, ASCOT
examined BP as the dependent variable, whereas mortality
was the focus of ACCOMPLISH.
ASCOT compared one additional ethnic group—South-
Asian ancestry—with whites and blacks. South-Asian
patients tended to have an increased response to adding
an ACE inhibitor to a CCB, but a decreased response to
adding a thiazide diuretic to a beta blocker, though these
differences were not statistically significant. There is a
possibility of type II error, as a result of the relatively small
number of South-Asian patients (only 154 in the entire
study, and only 82 going on to dual therapy), so additional
investigation will be needed to confirm these findings.
One limitation of ASCOT is that it did not consider
comorbid conditions that might suggest forms of BP
treatment desirable for indications in addition to BP
response alone, such as beta blockers for use in heart
failure or ACE inhibitors for patients with chronic kidney
disease or a history of myocardial infarction.
This study certainly highlights the need to personalize
therapy in order to gain the greatest response to the fewest
medications, but self-identified ethnicity may not be an
adequate reflection of biogeographic ancestry. Genetic
association studies have demonstrated that substantial
allelic variation may exist among individuals even within
the same self-identified ethnic group. In the United States,
genetic admixture in self-proclaimed African Americans
may include up to 25% of alleles derived from European
descent [10]. More appropriate may be the investigation of
pharmacogenetic-directed therapy. Pharmacogenetic studies
in hypertension have so far focused on response to
antihypertensive monotherapy. The financial cost and time
delay, plus the lack of consistent findings in the literature,
have so far limited the clinical contributions of pharmaco-
genetic therapy to the treatment of hypertension [11].
Continued research may ultimately reveal useful genetic
predictors of antihypertensive drug responses.
In this important article, Gupta et al. highlight that ethnic
group differences exist in response to both first-line and
second-line antihypertensive therapies, suggesting both drug–
druginteractionsanddrug–geneticinteractions,whichmaybe
quite complex. As evidence-based personalized medicine
becomes the goal in clinical medicine, further study is needed
to pursue such findings as well as the origin of intergroup
differences, with the ultimate goal of optimal treatment of
hypertension with minimal adverse effects.
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